EIP logo

Copyright © 2007-2026 European Immunogenicity Platform

Location photo

16th Open Scientific EIP Symposium on Immunogenicity of Biopharmaceuticals

24th — 26th February 2025

Lisbon, Portugal

Symposium sponsors

Program

Download the program as a PDF
 

Monday, February 24th 2025

Workshop Day
09:00 Coming Together
09:15 Challenging the current paradigms for clinical immunogenicity testing — the pros and cons
Daniel Kramer, Sanofi
Arno Kromminga, BioNTech
Sebastian Spindeldreher, Integrated Biologix
Christopher Tiedje, BioAgilytix
Lydia Michaut, Novartis
10:15 coffee Coffee Break
10:45 Continue “Challenging the current paradigms for clinical immunogenicity testing — the pros and cons”
12:15 cutlery 77 Lunch Break
13:30 Bring Your own Problems (Break out Sessions)
Daniel Kramer, Sanofi
Arno Kromminga, BioNTech
Sebastian Spindeldreher, Integrated Biologix
Sofie Pattijn, IQVIA
Noel Smith, Lonza
Sophie Tourdot, Pfizer
Tim Hickling, Roche
ydia Michaut, Novartis
15:00 coffee Coffee Break
15:30 Continue “Bring Your own Problems (Break out Sessions)”
16:30 Closing of the Workshop Day
17:00 18:30 Meeting of the EIP Working Groups
Members of EIP working groups
 

Tuesday, February 25th 2025

09:00 Welcome and Introduction by the EIP Chairman
Daniel Kramer, Sanofi
09:15 Spotlight Presentations: Machine Learning and Immunogenicity: Perspectives on the use of AI in Risk Assessment and Mitigation
Daniel Leventhal, Xaira Therapeutics
Session 2: Prediction of Immunogenicity
Chair: Sebastian Spindeldreher
10:15 EIP NCIRA Working Group Update
Sebastian Spindeldreher, Integrated Biologix on behalf of EIP
10:30 Analyzing and decreasing the immunogenicity potential of biotherapeutics using in silico approaches
Michael Gutknecht, Novartis
11:00 coffee Coffee Break
11:30 Enhancing Large Molecule Design by Early Integration of MAPPs using Defined Allele Antigen Presenting Cells
Andreas Hollenstein, Roche
12:00 The localization of T-cell epitopes in biopharmaceuticals: from peptides to gene therapy vectors
Bernard Maillere, University Paris-Saclay
12:30 cutlery 77 Lunch Break
13:30 Internalization of therapeutic antibodies into Dendritic cells as a risk factor for immunogenicity
Michel Siegel, Roche
14:00 Aggregation of therapeutic antibodies enhances dendritic cell uptake and T-cell responses
Marc Pallardy, University Paris Saclay
14:30 Suitable peptide controls for screening generic peptide products in adaptive immunogenicity assays
Chloë Ackaert, IQVIA Laboratories In Vitro Immunology (FKA ImmunXperts)
15:00 coffee Coffee Break
Session 3: Immunogenicity Assays
Chair: Arno Kromminga
15:30 EIP Immunogenicity Assays Working Group Update
Linlin Luo, Merck Sharp & Dome on behalf of EIP
15:45 Current industry practices for in-study cut point setting for clinical immunogenicity assays
Riejanne Bax-Seigers, ICON
16:15 Comparing Signal-to-Noise with titer results – a retrospective analysis
Karin Benstein, Sanofi
16:45 Addressing Target Interference During the Development of a Neutralizing Anti-Drug Antibody Assay for the clinical support of a bispecific therapeutic antibody
Saskia van der Lee, Genmab
Session 3: Social Event
Chair: Barbara Vercruyssen
18:00 multiple 11 Get Together
23:00 moon stars Good Night
 

Wedneday, February 26th 2024

Session 4: Immunogenicity Assays continued
Chair: Arno Kromminga
09:00 Fit-for-purpose non-clinical immunogenicity assessment to support PK data interpretation – a case study
Christopher Tiedje, BioAgilytix
09:30 Evaluating and Mitigating Pre-existing Anti-Drug Antibodies of Bi-Specific Therapeutic Proteins in Early Drug Discovery: A Roche Case Study
Janine Faigle, Roche
Short Talks (15 min)
10:00 A retrospective analysis of clinical immunogenicity data – time for singlicate change?
Sandra Ribes Miravet, Sandoz
10:15 Is ADA-tiered approach suitable to therapeutics with pre-existing antibodies?
Issa Jyamubandi, Intertek
10:30 coffee Coffee Break
11:00 Generation of anti-drug antibody (ADA) positive control and development of a bridging immunogenicity assay for RNA therapeutics in human serum
Gnana Oli Rajaraman, AiCuris Anti-infective Cures AG
11:15 Application of SPR technology for assessment of immunogenicity of a dual-peptide cancer vaccine
Daniel Worms, BioAgilytix
11:30 In-depth characterization and semi-quantification of ADAs using innovative hybrid LC-MS methods to support clinical development of biotherapeutics
Stéphane Muccio, Sanofi
Session 5: Clinical Relevance of Immunogenicity
Chair: Lydia Michaut
11:45 Analysis of Clinical Immunogenicity Data for a Multi-Study Program
Susan Irvin, Regeneron
12:15 The effects of the immune modulator methotrexate on anti-drug antibody formation
Floris Loeff, Sanquin
12:45 cutlery 77 Lunch Break
13:45 An American Association of Pharmaceutical Scientists (AAPS) Perspective on Clinical Relevance of Immunogenicity
Mohsen Rajabi, Novartis (on behalf of AAPS)
Session 5: Immunogenicity of Novel Modalities
Chair: Noel Smith
14:15 Success in treatment of cancer and autoimmunity with CAR T-cells: application to prevention and mitigation of immunogenicity of therapeutic proteins?
Amy Rosenberg, Epivax
14:45 Exploring alternatives to the 3-tiered immunogenicity testing paradigm for gene therapy programs
Robert Nelson, BioAgilytix
15:15 Cell-Based Assays for Neutralizing Antibodies: From Gene Therapy to Immune Effector Functions
Michael Tovey, Svar Life Science
Session 6: Regulatory
Chair: Daniel Kramer
15:45 Future impact of immunogenicity data on Biosimilar developments
René Anour, Pfizer
16:15 Conference Summary & Outlook by the EIP Chairman
Daniel Kramer, Sanofi
16:30 Close of the conference
Back to top